Clinical trial
Study Of Ispinesib In Subjects With Breast Cancer
NCT00089973 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00089973 |
|---|---|
| Title | Study Of Ispinesib In Subjects With Breast Cancer |
| Official title | Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Ispinesib |
| Enrollment | 50 |
| Start date | Jun 30, 2004 |
| Primary completion | Aug 25, 2006 |
| Completion | Aug 25, 2006 |
| First posted | Aug 20, 2004 |
| Last update posted | Feb 26, 2018 |
| Countries | Belgium, Malaysia, Singapore, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: